BioCloner Health is expanding its operations to the United States. The company has established a subsidiary in Cambridge, one of the world’s leading hubs for technological innovation. The new location operates within the ecosystem of The Engine, Built by MIT, fostering collaboration with scientific, industrial, and clinical partners across North America.<\/p>
The establishment of the U.S. subsidiary marks the next stage in BioCloner Health\u2019s development. At the same time, the company remains a Polish biotechnology enterprise, with its R&D activities, laboratories, and manufacturing operations continuing to be based in Poland, in Warsaw and Lublin. It is here that the company’s proprietary 3D bioprinting technology has been developed since 2016, including the design of bioprinters, proprietary software, and control electronics.<\/p>
Obecno\u015b\u0107 w rejonie Bostonu wynika z rosn\u0105cego znaczenia rynku ameryka\u0144skiego dla bran\u017cy bioprintingu. Ameryka P\u00f3\u0142nocna odpowiada za blisko 38% \u015bwiatowego rynku biodruku 3D i pozostaje miejscem, w kt\u00f3rym powstaje wiele prze\u0142omowych projekt\u00f3w z zakresu in\u017cynierii tkankowej i medycyny regeneracyjnej. Dzi\u0119ki nowej sp\u00f3\u0142ce BioCloner Health mo\u017ce by\u0107 bli\u017cej partner\u00f3w, klient\u00f3w i instytucji naukowych, jednocze\u015bnie zachowuj\u0105c swoje zaplecze technologiczne i produkcyjne w Polsce.<\/p>
BioCloner Health technology is used in projects carried out by leading Polish universities and research institutions, including Warsaw University of Technology, AGH University of Krakow, Cracow University of Technology, Adam Mickiewicz University in Pozna\u0144, Pozna\u0144 University of Medical Sciences, and the University of Applied Sciences in Che\u0142m (PANS). The company’s bioprinters support research on bacterial cellulose-based bioinks, corneal tissue bioprinting, organ-on-a-chip technologies, and the development of bionic implants. The results of some of these projects have been published in independent scientific journals.\n\nAn important part of this approach is the company’s multidisciplinary expertise. BioCloner Health’s CEO, Maciej Tabiszewski, is a medical doctor by training. This background enables the company to combine perspectives from medicine, biology, and engineering\u2014disciplines that often operate separately in the field of bioprinting.<\/p>
The company’s flagship solution is the BioCloner Desktop Pro, a modular 3D bioprinter designed to work with hydrogels, bioinks, filaments, and granules. Engineered for advanced research applications, the system supports temperature-controlled bioprinting of cell-laden materials, UV curing, and features a fully enclosed chamber equipped with H14 HEPA filtration and UV-C sterilization to help maintain a clean and controlled printing environment.<\/p>
BioCloner Health’s business model extends beyond the development and manufacturing of 3D bioprinting systems. The company also supplies consumables and bioinks, conducts research and development projects, provides engineering services, and delivers training for research institutions and industrial partners. Its strategy is focused on advancing technologies for science and medicine while building international partnerships and maintaining its R&D and manufacturing capabilities in Poland.<\/p>
<\/p>","protected":false},"excerpt":{"rendered":"
BioCloner Health is expanding its operations to the United States. Polish 3D bioprinting technology is entering the U.S. market…<\/p>","protected":false},"author":2,"featured_media":6108,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-6105","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company"],"acf":[],"yoast_head":"\n